The application of prodrug-based nano-drug delivery strategy in cancer combination therapy

[Display omitted] ⿢The application of prodrug-based nano-drug delivery systems (P-N-DDSs) in combination therapy is discussed.⿢The combinations of prodrugs with chemotherapeutic agents based on P-N-DDSs are reviewed.⿢The combinations of prodrugs with other therapeutic agents based on P-N-DDSs are reviewed.⿢The combinations of prodrugs with nucleic acids based on P-N-DDSs are reviewed.⿢The combinations of chemotherapy and phototherapy based on P-N-DDSs are reviewed. Single drug therapy that leads to the multidrug resistance of cancer cells and severe side-effect is a thing of the past. Combination therapies that affect multiple signaling pathways have been the focus of recent active research. Due to the successful development of prodrug-based nano-drug delivery systems (P-N-DDSs), their use has been extended to combination therapy as drug delivery platforms. In this review, we focus specifically on the P-N-DDSs in the field of combination therapy including the combinations of prodrugs with different chemotherapeutic agents, other therapeutic agents, nucleic acid or the combination of different types of therapy (e.g. chemotherapy and phototherapy). The relevant examples of prodrug-based nanoparticulate drug delivery strategy in combination cancer therapy from the recent literature are discussed to demonstrate the feasibilities of relevant technology.